Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Receivables (2019 - 2025)

Immunocore Holdings (IMCR) has disclosed Receivables for 7 consecutive years, with $74.0 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 17.41% to $74.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $74.0 million through Dec 2025, up 17.41% year-over-year, with the annual reading at $74.0 million for FY2025, 17.41% up from the prior year.
  • Receivables hit $74.0 million in Q4 2025 for Immunocore Holdings, down from $75.9 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $75.9 million in Q3 2025 to a low of $10.1 million in Q4 2021.
  • Historically, Receivables has averaged $57.4 million across 5 years, with a median of $63.0 million in 2024.
  • Biggest five-year swings in Receivables: plummeted 36.06% in 2021 and later skyrocketed 309.98% in 2022.
  • Year by year, Receivables stood at $10.1 million in 2021, then surged by 309.98% to $41.5 million in 2022, then grew by 25.4% to $52.1 million in 2023, then increased by 20.95% to $63.0 million in 2024, then increased by 17.41% to $74.0 million in 2025.
  • Business Quant data shows Receivables for IMCR at $74.0 million in Q4 2025, $75.9 million in Q3 2025, and $69.8 million in Q2 2025.